IP Library › Granted Patent US 7,094,899
Granted Patent B2
US 7,094,899 · App. 10/301,614 · Granted Aug 22, 2006

Vitreous form of known bradykinin antagonist

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,094,899
App. No.
10/301,614
Granted
Aug 22, 2006
Kind
B2
Abstract

This invention relates to a vitreous form of 8-[3-[N-[(E)-3-(6-acetamidopyridin-3-yl)acryloylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline (FR173657). This vitreous form has good solid stability and, therefor, is useful for producing and supplying FR173657 products whose quality is stable enough to be suitable for medicines.

Claims (5)

1. A composition comprising:

a vitreous form of 8-[3-[N-[(E)-3-(6-acetamido-pyridin-3-yl)acryloylglycyl]-N-methylamino]-2,6dichlorobenzyloxy]-2-methylquinoline, which is substantially free of a crystalline form thereof and which has an endothermic peak top due to glass transition at around 126 to 128° C. as determined by differential scanning calorimety (DSC; heating rate: 10° C./min) and which has an infrared absorption spectrum comprising the following peaks: 1684, 1662, 1524, 1236, and 836 cm −1 ; and

a pharmaceutically acceptable carrier or excipient.

2. The composition of claim 1 in the form of a tablet.

3. The composition of claim 1 in the form of granules.

Assignments (1)
MERGER Recorded Jun 28, 2005
From: FUJISAWA PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 016427/0305 →